       Document 0225
 DOCN  M9640225
 TI    Protection of MN-rgp120-immunized chimpanzees from heterologous
       infection with a primary isolate of human immunodeficiency virus type 1.
 DT    9604
 AU    Berman PW; Murthy KK; Wrin T; Vennari JC; Cobb EK; Eastman DJ; Champe M;
       Nakamura GR; Davison D; Powell MF; Bussiere J; Francis DP; Matthews T;
       Gregory TJ; Obijeski JF; Department of Immunology, Genentech, Inc.,
       South San Francisco,; California 94080, USA.
 SO    J Infect Dis. 1996 Jan;173(1):52-9. Unique Identifier : AIDSLINE
       MED/96132463
 AB    Three chimpanzees immunized with recombinant gp120 from human
       immunodeficiency virus type 1 (HIV-1) strain MN and 1 control animal
       were challenged intravenously with a primary isolate of HIV-1SF2. Viral
       infection was detected in the control animal by viral culture,
       polymerase chain reaction, and multiple serologic assays beginning 2
       weeks after infection. Markers of HIV-1 infection were not detected in
       any of the gp120-vaccinated animals during 12 months of follow-up.
       Antisera from the gp120-immunized chimpanzees were unable to neutralize
       the challenge virus cultured in peripheral blood mononuclear cells
       (PBMC). These studies demonstrate that immunization with recombinant
       gp120 derived from a T cell-adapted isolate prevented infection by a
       heterologous primary isolate of HIV-1. The results suggest that in vitro
       virus neutralization assays utilizing primary isolates cultured in PBMC
       may be imperfect indicators of protection in vivo.
 DE    Animal  *AIDS Vaccines  Base Sequence  Chimpansee troglodytes  DNA
       Primers/CHEMISTRY  DNA, Viral/ANALYSIS  HIV Antibodies/ANALYSIS  HIV
       Antigens/IMMUNOLOGY  HIV Envelope Protein gp120/*IMMUNOLOGY  HIV
       Infections/IMMUNOLOGY/*PREVENTION & CONTROL
       HIV-1/GENETICS/*IMMUNOLOGY/ISOLATION & PURIF  *Immunization
       Immunization Schedule  Immunization, Secondary  Molecular Sequence Data
       Neutralization Tests  T-Lymphocytes/VIROLOGY  *Vaccines, Synthetic
       Virus Cultivation  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

